Tag Archives: bipolar disorder

Healthcare Products, Public Health, Society

Goodspace Anxiety Aid and Richard Reid Collaborate to Support Men’s Mental Health for International Men’s Day

Leave a comment

SYDNEY, NSW, Australia, 2024-Oct-25 — /EPR Network/ — In recognition of International Men’s Day, Goodspace Anxiety Aid has teamed up with celebrated TV personality and mental health advocate Richard Reid to help raise awareness about men’s mental health. Throughout November, Goodspace is offering a 20% discount on its unique anxiety-relief gum to help support those experiencing stress and mild anxiety. The promotion is available online at www.goodspacegum.com using code MEN20.

Goodspace Anxiety Aid is formulated as a fast-acting, chewable gum that combines five natural ingredients known for their stress-relief benefits, including KSM-66 Ashwagandha, Green Tea, and Passionflower. Engineered to release active ingredients gradually through the gums and cheeks, Goodspace delivers calming effects quickly and conveniently.

Richard Reid, known for his TV appearances on Today and Studio 10 and as an advocate for mental health, is using his voice to help break the stigma around men’s mental health. Reid has spoken openly about his personal struggles and the impact of mental health on his family, and he continues to encourage others to discuss their own experiences.

“Men often face the pressures of mental health in silence,” Reid said. “Partnering with Goodspace Anxiety Aid is a way to help guys feel supported, knowing there are simple, effective options for everyday stress relief. I hope it starts conversations that matter.”

Goodspace gum is widely available at over 1,000 locations across Australia, including Coles and WH Smith. The gum is a convenient option for those looking to manage anxiety on the go, designed to provide fast and effective relief without the need for water or pills.

A spokesperson for Goodspace added, “We’re thrilled to partner with Richard Reid for this campaign. His dedication to mental health awareness is inspiring, and we believe Goodspace can be a useful resource for men facing daily stress.”

Goodspace Anxiety Aid retails for AUD $9.99 and is intended for adults 18+. The discount code MEN20 is valid until November 30. Always read the label, follow directions, and consult a healthcare provider if symptoms persist.

SOURCE: EPR Network

Biotech, Consultations, Disorders, Healthcare, Healthcare Information, Healthcare Professionals, Healthcare Services, Healthcare Solutions, Psychiatry, Public Health, Society

European public-private project to advance precision psychiatry by introducing biology into clinical routine

Leave a comment

PARIS AND MONTPELLIER, 30-Mar-2022 — /EPR HEALTHCARE NEWS/ — ALCEDIAG announces the launch of the EDIT-B Consortium, supported by the European Institute of Innovation and Technology for Health (EIT Health). This newly formed European public-private partnership aims at advancing precision psychiatry by introducing biology into clinical routine.

Around 300M people in the world are affected by depression. Studies show that up to 40% of them may be misdiagnosed and potentially bipolar. As a result, diagnosis is often delayed by an average of 7.5 years, worsening patients’ mental and physical conditions as well as their loved ones’ quality of life.

The EDIT-B Consortium aims to solve this diagnostic challenge by using specific RNA editing based biomarkers and artificial intelligence to validate and commercialize an accurate, reliable, and quick blood test to diagnose bipolar disorder.

The Consortium brings together prominent members from across Europe who will be working over the next three years to achieve this goal: Alcediag, Alcen, Capital Region of Denmark, Fundació Clinic per la Recerca Biomèdica, Fundació Sant Joan de Déu, GHU Paris Psychiatrie & Neurosciences, Hospital Clínic de Barcelona, Parc Sanitari Sant Joan de Déu, ProductLife Group and Synlab. With a total budget of € 5.2 million, EDIT-B is co-funded by the EIT Health (€ 2.5M) and the partners.

“This project will accurately separate bipolar disorder from unipolar disorder. This distinction is extremely important clinically, because the treatments are different. EDIT-B Consortium gathers all relevant expertise and as the principal investigator in the clinical trial, I hope we will be able to validate a test that will improve the lives of many people living with bipolar disorder”, says Prof. Eduard Vieta from the Hospital Clínic de Barcelona.

SYNLAB is the first diagnostic service provider in Europe, present in 36 countries in 4 continents and committed to developing high value solutions for patients  focusing on medical excellence and customer centricity.

Maurizio Ferrari, SYNLAB Italy Chief Medical Officer says: “innovation in healthcare is a key pillar for the customer centricity and  we are very proud to be part of this European research project that really may help patients with psychiatric disorders”.

“I am proud to see that the EDIT-B consortium led by our partner Alcediag – a subsidiary of Alcen – will tackle the challenge of improving the diagnosis of bipolar disorder. In doing so, they support EIT Health main mission which is to help citizens live healthier and longer lives and at the same time put the spotlight on mental health which is key to the proper care management and wellbeing of our communities”, adds Jean Marc Bourez, interim CEO of EIT Health.

“On this World Bipolar Day, Alcediag team is happy to announce its contribution to solving the bipolar disorder diagnostic issue.  We are proud and grateful to our partners and the EIT Health for this opportunity to advance science while having a positive impact on people’s lives”, said Alexandra Prieux, CEO of Alcediag.

SOURCE: EuropaWire